These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 1975844

  • 1. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia.
    Schulz TF, Whitby D, Hoad JG, Corrah T, Whittle H, Weiss RA.
    J Virol; 1990 Oct; 64(10):5177-82. PubMed ID: 1975844
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, Boulos R, Nzila N, Quinnan GV.
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype.
    Breuer J, Douglas NW, Goldman N, Daniels RS.
    J Gen Virol; 1995 Feb; 76 ( Pt 2)():333-45. PubMed ID: 7531216
    [Abstract] [Full Text] [Related]

  • 9. Antigenic and immunogenic sites of HIV-2 glycoproteins.
    Chiodi F, Björling E, Samuelsson A, Norrby E.
    Chem Immunol; 1993 Feb; 56():61-77. PubMed ID: 8452654
    [Abstract] [Full Text] [Related]

  • 10. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC.
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [Abstract] [Full Text] [Related]

  • 11. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
    Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Broström C, Fenyö EM, Albert J.
    J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
    [Abstract] [Full Text] [Related]

  • 12. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J, Lawoko A, Pipkorn R, Moyo S, Malmvall BE, Shao J, Dash R, Tswana S.
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [Abstract] [Full Text] [Related]

  • 13. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M, Aldrich K, Muldoon R, Stern TL, Bansal GP, Matthews TJ, Markham PD, Gallo RC, Franchini G.
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.
    Matsumi S, Matsushita S, Yoshimura K, Javaherian K, Takatsuki K.
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):501-8. PubMed ID: 7632464
    [Abstract] [Full Text] [Related]

  • 15. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
    Whittle H, Egboga A, Todd J, Corrah T, Wilkins A, Demba E, Morgan G, Rolfe M, Berry N, Tedder R.
    AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
    [Abstract] [Full Text] [Related]

  • 16. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC, Golden AM, Lund JK, Gürtler LG, Zekeng L, Obiang J, Kaptué L, Hampl H, Vallari A, Devare SG.
    AIDS Res Hum Retroviruses; 1997 Aug 10; 13(12):995-1005. PubMed ID: 9264286
    [Abstract] [Full Text] [Related]

  • 17. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ, Anderson SA, Nkya WM, Shao JF, Hendrix CW, Melcher GP, Redfield RR, Kennedy RC.
    J Virol; 1992 Sep 10; 66(9):5210-5. PubMed ID: 1380094
    [Abstract] [Full Text] [Related]

  • 18. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, Bilska M, Zhou JT, Pauza CD, Parren PW, Burton DR, Sodroski JG, Letvin NL, Montefiori DC.
    J Virol; 1999 Dec 10; 73(12):10199-207. PubMed ID: 10559336
    [Abstract] [Full Text] [Related]

  • 19. Nucleotide sequence of the HIV-2 EHO genome, a divergent HIV-2 isolate.
    Galabru J, Rey-Cuillé MA, Hovanessian AG.
    AIDS Res Hum Retroviruses; 1995 Jul 10; 11(7):873-4. PubMed ID: 7546916
    [Abstract] [Full Text] [Related]

  • 20. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).
    Böttiger B, Karlsson A, Andreasson PA, Naucler A, Costa CM, Biberfeld G.
    AIDS Res Hum Retroviruses; 1989 Oct 10; 5(5):525-33. PubMed ID: 2590556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.